BioTalent Canada

B IOTALENT CANADA them all on our website. The work that BioTalent Canada puts forth helps these companies succeed in times of crisis. We’re proud of that.” BVM: How has BioTalent Canada managed during the COVID-19 crisis? Henderson: “Like everyone else, BioTalent Canada had to adapt to work-from-home. At first, it was a challenge, but I think we’ve done a great job of turning that challenge into an opportunity. It was important for us to connect with employers and other stakeholders. We needed them to know that our programs are still active and BioTalent Canada continues to operate and support the industry. “Luckily for us, that was relatively easy. Our teams have worked for years to build foundational relationships with our partners. We were always in constant communication before the pandemic hit. We’ve been able to thrive because so many of our wage subsidy clients had to ramp up recruitment during COVID-19, to foot 100 percent of the bill. We’ve helped more than 2,500 Canadians begin their careers in the bio-economy through our wage subsidies. “As for recent successes, we need look no further than to what’s taken place since COVID-19. Our partners and wage subsidy employers have been making great strides. Just to name a few: • Abcellera received money from the Government of Canada to discover COVID-19 solutions and build a facility to manufacture antibody drugs • STEMCELL Technologies developed advanced cell culture systems to isolate and identify the novel coronavirus. • Greenfield Global was selected to partner with Longhorn Vaccines and Diagnostics LLC to accelerate COVID-19 testing and detection “We get reports of stories like these— seemingly—on a weekly basis. You can read